Interactions
Pharmacological context. This hub organizes the topic into a starting point, core reading, and deeper reference material so mobile readers and search systems can understand the page pathway quickly.
Get oriented first
Begin with the plain-language framing before reading narrower claims or legal and safety details.
Read the central articles
Use the core set to understand the topic before moving into edge cases and supporting references.
Education, not instruction
This section does not provide medical, dosing, sourcing, purchasing, or legal advice.
Psilocybin drug interactions: evidence is thin and mostly mechanistic or case-report. A few are genuinely dangerous; absence of reports is not safety.
Alcohol is a depressant, not a serotonergic drug, so the co-use concern is additive impairment — and the 'drink less' idea borrows from full-dose trials.
Antipsychotics and Microdosing: The Receptor-Blocking PredictionMany antipsychotics block the 5-HT2A receptor psychedelics act on — a controlled study shows this can abolish psilocybin's effects. What it means.
Cannabis and Microdosing: A Common Pairing With Thin EvidenceCannabis is among the most common substances combined with microdosing, yet almost none of it is studied. What the pharmacology and the caveats actually support.
Case reports link lithium plus classic psychedelics to seizures — the strongest documented-danger signal in this cluster, and what it does and doesn't prove.
MAOIs and Microdosing: Why Monoamine Oxidase Inhibitors Warrant Real CautionMAOIs alter how the body clears psilocin and raise serotonergic load — a mechanistically high-caution interaction, though microdose incidence data are absent.
Psychiatric Medications and Psilocybin: A Class-by-Class Interaction MapA class-by-class map of how psychiatric medications can change psilocybin's risk, intensity, and interpretation — what the evidence shows and where it stops.
Serotonergic Drugs and Serotonin Syndrome: Mechanism Versus Documented RiskSerotonin syndrome is real and serious, but its documented incidence with psilocybin microdoses is essentially absent. Separating mechanism from measured risk.
SSRIs, SNRIs and Microdosing: What the Evidence Says About BluntingChronic SSRI/SNRI use appears to blunt psychedelic effects through 5-HT2A adaptation — a pharmacological interaction, not a danger signal. What the data show.
Stimulants, ADHD Medications and Microdosing: What's KnownStimulants and psychedelics act on largely different systems, so the interaction is mostly theoretical — but the data are thin and the focus question needs care.